-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WivP4Ta+kH8GWHcUH0uTpOQ78yHLbefF7QPhBuYONB/fo6GNacqnZOc6GtbUOH1g HavzJuICFSNuD5H0FIq2lQ== 0000905718-10-000129.txt : 20100607 0000905718-10-000129.hdr.sgml : 20100607 20100607164016 ACCESSION NUMBER: 0000905718-10-000129 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20100607 DATE AS OF CHANGE: 20100607 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Myriad Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001459450 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263996918 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-84958 FILM NUMBER: 10881766 BUSINESS ADDRESS: STREET 1: 305 CHIPETA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 BUSINESS PHONE: 801-584-3600 MAIL ADDRESS: STREET 1: 305 CHIPETA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TYNDALL CAPITAL PARTNERS L P CENTRAL INDEX KEY: 0001219314 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 599 LEXINGTON AVENUE SUITE 4100 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 2124462460 MAIL ADDRESS: STREET 1: 599 LEXINGTON AVENUE SUITE 4100 CITY: NEW YORK STATE: NY ZIP: 10022 SC 13G 1 myriad13g.htm MYRIAD13G myriad13g.htm
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.   )*


MYRIAD PHARMACEUTICALS, INC.
(Name of Issuer)
 
COMMON STOCK, PAR VALUE $0.01 PER SHARE
(Title of Class of Securities)
 
62856H107
(CUSIP Number)
 
May 28, 2010
(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to  which this Schedule
13G is filed:

 
[   ]   Rule 13d-1(b)
 
[X]   Rule 13d-1(c)
 
[   ]   Rule 13d-1(d)




*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise  subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 

 

CUSIP NO.  62856H107
 
(1)           Names of Reporting Persons.  I.R.S. Identification Nos. of  Above  Persons
(entities only):
 
Tyndall Capital Partners, L.P.
13-3594570
 
 
(2)           Check  the  Appropriate Box  if  a  Member of  a  Group (See Instructions)
(a)  [ ]                           (b) [ ]
 
(3)           SEC Use Only
 
(4)           Citizenship or Place of Organization:  Delaware
 
Number of Shares Beneficially Owned
Each Reporting Person With by
(5)
Sole Voting Power
1,261,380*
 
 
(6)
Shared Voting Power:
0
 
 
(7)
Sole Dispositive Power:
1,261,380*
 
 
(8)
Shared Dispositive Power:
0
 
       
       
       
(9)           Aggregate Amount Beneficially Owned by Each Reporting Person:  1,261,380*
 
 
 
(10)        Check if  the  Aggregate Amount  in  Row  (9) Excludes Certain Shares (See Instructions):    N/A
 
 
 
(11)         Percent of Class Represented by Amount in Row (9):   5.1%*
 
 
 
(12)         Type of Reporting Person (See Instructions):  PN
 
 
* Based on the information set forth in the Form 10-Q of Myriad Pharmaceuticals, Inc. (the “Company”) as filed with the Securities and Exchange Commission on May 17, 2010, there were 24,965,825 shares of the Company’s common stock, par value $0.01 per share (the Shares), issued and outstanding as of May 11, 2010.  As of May 28, 2010, 870,382 Shares are owned by Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"), and 390,998 Shares are owned by Tyndall Institutional Partners, L.P., a Delaware limited partnership ("Tyndall Institutional").  Tyndall Capital Partners, L.P. is the general partner of Tyndall and Tyndall Institutional, and possesses the sole power to vo te and the sole power to direct the disposition of all Shares held by Tyndall and Tyndall Institutional.




 
 

 


Item 1(a)       Name Of Issuer:   Myriad Pharmaceuticals, Inc.

Item 1(b)              Address of Issuer's Principal Executive Offices:
305 Chipeta Way
Salt Lake City, Utah 84108


Item 2(a)    Name of Person Filing:  Tyndall Capital Partners, L.P.

Item 2(b)      Address of Principal Business Office or, if None, Residence:
                               599 Lexington Avenue, Suite 4100, New York, New York 10022

Item 2(c)               Citizenship: Delaware

Item 2(d)               Title of Class of Securities:   Common Stock, par value $0.01 per share

Item 2(e)                CUSIP No.:   62856H107
 
 
Item 3.
If This Statement Is Filed Pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

                               Not Applicable.


Item 4.                   Ownership.

 
(a)
  Amount Beneficially Owned (as of May 28, 2010):
1,261,380*
       
 
(b)
  Percent of Class (as of May 28, 2010):
5.1%*
       
 
(c)
  Number of Shares as to which such person has:
 
       
 
(i)
  sole power to vote or to direct the vote:
1,261,380*
       
 
(ii)
  shared power to vote or to direct the vote:
0
       
 
(iii)
  sole power to dispose or to direct the disposition of:
  1,261,380*
       
 
(iv)
  shared power to dispose or to direct the disposition of:
  0

___________
 
* Based on the information set forth in the Form 10-Q of Myriad Pharmaceuticals, Inc. (the “Company”) as filed with the Securities and Exchange Commission on May 17, 2010, there were 24,965,825 shares of the Company’s common stock, par value $0.01 per share (the Shares), issued and outstanding as of May 11, 2010.  As of May 28, 2010, 870,382 Shares are owned by Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall"), and 390,998 Shares are owned by Tyndall Institutional Partners, L.P., a Delaware limited partnership ("Tyndall Institutional").  Tyndall Capital Partners, L.P. is the general partner of Tyndall and Tyndall Institutional, and possesses the sole power to vo te and the sole power to direct the disposition of all Shares held by Tyndall and Tyndall Institutional.



 
 

 


Item 5.                 Ownership of Five Percent or Less of a Class

Not Applicable.


Item 6.                  Ownership of More Than Five Percent on Behalf of Another Person

                              Not Applicable.


Item 7.                  Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control Person

                              Not Applicable.


Item 8.                  Identification and Classification of Members of the Group

                              Not Applicable.


Item 9.                  Notice of Dissolution of Group

                              Not Applicable.


Item 10.                Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of, or with the effect of, changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with, or as a participant in, any transaction having that purpose or effect.



 
 

 


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
 
June 7, 2010
 
     
     
 
TYNDALL CAPITAL PARTNERS, L.P.
 
     
 
By:     
JEFFREY MANAGEMENT, LLC,
 
   
its general partner
 
       
 
By:    
/s/ Jeffrey S. Halis
 
   
Jeffrey S. Halis, Manager
 




Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)



 
 

 

-----END PRIVACY-ENHANCED MESSAGE-----